Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients
复制标题
DOI：
10.1093/annonc/mdr346
复制
发表时间：
2012-04-01
影响因子：
50.5
通讯作者：
Berdel, W. E.
中科院分区：
文献类型：
--
作者：
Brunnberg, U.;Mohr, M.;Berdel, W. E.
背景：老年急性髓细胞白血病（AML）患者化疗的中位总生存期（OS）为
Background: Chemotherapy for elderly patients with acute myeloid leukemia (AML) results in a median overall survival (OS) of